Anti Osteoporosis Therapy and Fracture Healing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Type (Calcitonin, Bisphosphonates, Hormone Replacement Therapy, Anabolic, Others), By Route of Administration (Oral, Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, E-Commerce), By Region & Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 15.34 Billion
CAGR (2026-2031)	4.49%
Fastest Growing Segment	Calcitonin
Largest Market	North America
Market Size (2031)	USD 19.97 Billion

Market Overview

The Global Anti Osteoporosis Therapy and Fracture Healing Market will grow from USD 15.34 Billion in 2025 to USD 19.97 Billion by 2031 at a 4.49% CAGR. The Global Anti Osteoporosis Therapy and Fracture Healing Market comprises pharmaceutical formulations and medical devices designed to preserve bone density and accelerate the structural repair of skeletal fractures. Market growth is primarily driven by an aging global population and the consequent rise in the prevalence of osteopenia and fragility fractures. Additionally, the escalating economic burden of bone disorders necessitates effective therapeutic interventions to mitigate long term healthcare costs. According to the Bone Health and Osteoporosis Foundation, in 2025, the total national costs of osteoporotic fractures were projected to rise to over $95 billion by 2030.

However, a significant challenge impeding market expansion is the high rate of patient nonadherence to antiresorptive therapies due to concerns regarding rare adverse events. This hesitation among patients and providers to initiate or maintain treatment results in a substantial treatment gap that limits the effective reach of available therapies. Consequently, overcoming these barriers to uptake remains a critical obstacle for industry stakeholders aiming to maximize market penetration and improve patient outcomes globally.

Key Market Drivers

The rapidly aging global population and the consequent increase in life expectancy are fundamentally reshaping the market by expanding the patient pool susceptible to skeletal fragility. As demographic shifts occur, the incidence of low bone mass and associated injuries rises, necessitating urgent therapeutic intervention and management strategies. This demographic pressure creates a massive clinical burden that drives the volume of diagnostic screenings and preventive care. According to the International Osteoporosis Foundation, August 2024, in the 'World Osteoporosis Day' campaign announcement, up to 37 million fragility fractures occur globally each year, underscoring the critical scale of the issue. The economic and social impact of these injuries further compels healthcare systems to close the treatment gap. According to the Royal Osteoporosis Society, March 2024, in the 'Ledger of Misery' statement, the lack of effective fracture liaison services results in 4,200 preventable hip fractures annually in the UK alone, highlighting the urgent need for systemic support.

Advancements in novel anabolic and antiresorptive drug therapies serve as a second critical catalyst, providing clinicians with more potent options to manage high-risk patients. Pharmaceutical companies are heavily investing in biologics that not only inhibit bone resorption but also stimulate new bone formation, offering superior efficacy for patients with severe osteoporosis. This innovation translates into substantial revenue growth and validates the commercial viability of next-generation treatments. According to Amgen, October 2024, in the 'Third Quarter 2024 Financial Results', sales of the antiresorptive therapy Prolia increased 6 percent year-over-year to generate $1.0 billion for the quarter. The continued commercial success of such branded therapies demonstrates a strong market preference for agents that offer established safety profiles and measurable improvements in bone mineral density.

Download Free Sample Report

Key Market Challenges

The primary challenge hampering the growth of the Global Anti Osteoporosis Therapy and Fracture Healing Market is the persistent rate of patient nonadherence driven by fears of rare adverse events. Although antiresorptive therapies are clinically proven to reduce fracture risks, anxiety regarding potential side effects—such as osteonecrosis of the jaw or atypical femoral fractures—causes substantial hesitation among both patients and healthcare providers. This psychological barrier prevents the initiation of necessary drug regimens and leads to high discontinuation rates, thereby severing the revenue stream for pharmaceutical manufacturers and limiting the adoption of advanced therapeutic devices.

This hesitation directly restricts market volume by creating a massive disparity between the eligible patient population and those actually receiving care. The resulting treatment gap ensures that a vast segment of the market remains under-penetrated, stalling potential revenue growth despite the rising prevalence of bone disorders. The magnitude of this missed opportunity is significant. According to the International Osteoporosis Foundation, in 2025, up to 80% of patients worldwide who suffer a fragility fracture remain undiagnosed and untreated for the underlying disease. This statistic highlights a critical failure to convert high disease prevalence into sustained market participation, fundamentally undermining the industry’s expansion trajectory.

Key Market Trends

The market is experiencing a structural transformation driven by the emergence of biosimilars for key osteoporosis biologics, particularly as patents for blockbuster RANK ligand inhibitors expire. This trend is dismantling exclusivity barriers, forcing price competition, and significantly expanding patient access to high-efficacy treatments that were previously cost-prohibitive for chronic management. The introduction of these cost-effective alternatives encourages healthcare systems to broaden reimbursement criteria, thereby increasing the volume of treated patients. According to Managed Healthcare Executive, February 2025, in the 'FDA Approves Second Biosimilars for Prolia/Xgeva' article, the FDA approved Samsung Bioepis' biosimilars Ospomyv and Xbryk for the treatment of osteoporosis and bone metastases, signaling a rapid intensification of market competition. This wave of regulatory approvals not only reduces healthcare expenditure but also mandates that originator companies pivot towards newer mechanisms to maintain market share.

Concurrently, there is a prioritized wave of innovation in non-invasive drug delivery systems designed to overcome the persistent challenge of patient aversion to injectable anabolic therapies. Industry players are advancing oral formulations of parathyroid hormone analogs that promise to deliver efficacy comparable to subcutaneous injections while drastically improving adherence rates among elderly populations. This shift addresses the logistical and psychological barriers associated with daily self-injections, which historically led to high discontinuation rates. According to Entera Bio, September 2025, in the 'Entera Bio Presents Positive Effects of EB613 on Both Trabecular and Cortical Bone' press release, Phase 2 data presented at the ASBMR Annual Meeting demonstrated that the oral PTH(1-34) tablet EB613 achieved significant increases in cortical bone parameters after six months, comparable to established injectable agents. The successful commercialization of such oral alternatives represents a pivotal shift in treatment paradigms, offering a convenient, patient-centric option for severe osteoporosis management.

Segmental Insights

Based on recent market research, the Calcitonin segment is identified as the fastest-growing category within the global anti-osteoporosis therapy and fracture healing industry. This rapid expansion is primarily driven by the increasing adoption of Calcitonin as a critical alternative for patients who are intolerant to bisphosphonates and other first-line medications. Furthermore, the therapy is gaining traction due to its unique dual efficacy in regulating bone metabolism and managing pain associated with acute vertebral fractures. The segment’s growth is further supported by the availability of convenient nasal spray formulations, which enhance patient compliance and accessibility in emerging international markets.

Regional Insights

North America maintains a dominant position in the global anti-osteoporosis therapy and fracture healing market due to the high incidence of bone-related conditions and a well-established healthcare infrastructure. The region benefits from the strong presence of major pharmaceutical companies and widespread patient awareness regarding bone health. Furthermore, clear regulatory pathways provided by the U.S. Food and Drug Administration facilitate the timely approval of new treatments, while favorable reimbursement policies ensure broader patient access to care. These factors collectively support the region’s leadership and drive the adoption of therapeutic solutions across the United States and Canada.

Recent Developments

• In October 2025, Entera Bio presented positive new clinical data from a Phase 2 trial of EB613, an investigational oral formulation of parathyroid hormone, at the North American Menopause Society Annual Meeting. The study results demonstrated that the oral tablets produced significant improvements in bone mineral density at key fracture sites, such as the lumbar spine and total hip, in postmenopausal women with osteoporosis or low bone mass. The company emphasized that these findings supported the potential of the therapy to serve as the first oral anabolic treatment for osteoporosis, offering a convenient, non-injectable option to build bone and reduce fracture risk in high-need patient populations.
• In March 2025, Celltrion received approval from the U.S. FDA for its denosumab biosimilars, marketed as Stoboclo and Osenvelt, expanding the options available for osteoporosis management and fracture prevention. These biologics were referenced to established treatments and were authorized for the same indications, including increasing bone mass in patients at high risk for fracture and preventing skeletal-related events in patients with multiple myeloma and solid tumor metastases. The company confirmed that the products were expected to be available in the U.S. market by mid-2025, following a settlement agreement with the manufacturer of the reference products, which secured a pathway for the launch of these cost-effective therapeutic alternatives.
• In August 2024, Stryker announced the commercial launch of the Pangea Plating System, a new trauma portfolio designed to support fracture healing across a wide range of patient populations. The system featured a comprehensive array of anatomically contoured implants and instrumentation intended to improve plate fit and screw placement for surgeons. The company indicated that this launch aimed to elevate standards in the plating market by providing a versatile solution for the internal fixation and stabilization of bone fractures, osteotomies, and arthrodesis in both normal and osteopenic bone, thereby addressing the specific needs of patients with compromised bone quality.
• In March 2024, Sandoz announced that the U.S. Food and Drug Administration (FDA) had approved Wyost and Jubbonti, representing the first interchangeable biosimilars to denosumab to be authorized in the United States. These therapies were approved to cover all indications of the reference medicines, which include the treatment of osteoporosis in postmenopausal women and men at high risk of fracture, as well as the prevention of skeletal-related events in patients with cancer-related bone metastases. The company stated that this regulatory milestone would enhance patient access to essential biologic treatments that address primary and secondary bone loss, supported by clinical studies demonstrating no meaningful differences in safety and efficacy compared to the reference products.

Key Market Players

• GlaxoSmithKline plc
• Medtronic Plc.
• Merck & Co. Inc.
• Novartis AG
• Pfizer inc.
• Eli Lilly and Co.
• F. Hoffmann-La Roche Ltd
• Stryker Corporation
• Teva Pharmaceutical Industries Ltd.
• Orthofix US LLC

By Drug Type	By Route of Administration	By Distribution Channel	By Region
Calcitonin Bisphosphonates Hormone Replacement Therapy Anabolic Others	Oral Injectable	Hospital Pharmacies Retail Pharmacies E-Commerce	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Anti Osteoporosis Therapy and Fracture Healing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Anti Osteoporosis Therapy and Fracture Healing Market, By Drug Type:

• Calcitonin
• Bisphosphonates
• Hormone Replacement Therapy
• Anabolic
• Others

• Anti Osteoporosis Therapy and Fracture Healing Market, By Route of Administration:

• Oral
• Injectable

• Anti Osteoporosis Therapy and Fracture Healing Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• E-Commerce

• Anti Osteoporosis Therapy and Fracture Healing Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE